Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (DefeHEMY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01892644
Recruitment Status : Terminated (Failure to recruit patients with hemochromatosis to the Deferasirox arm)
First Posted : July 4, 2013
Last Update Posted : January 23, 2017
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Haukeland University Hospital

Tracking Information
First Submitted Date  ICMJE July 1, 2013
First Posted Date  ICMJE July 4, 2013
Last Update Posted Date January 23, 2017
Study Start Date  ICMJE May 2013
Actual Primary Completion Date January 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 1, 2013)
Changes from baseline in liver iron concentration (LIC) and heart iron concentration (HIC) determined by Magnetic Resonance Imaging (MRI), and in bone marrow iron content determined by microscopy after treatment with deferasirox. [ Time Frame: 0, 6 and 12 months ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01892644 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 1, 2013)
  • Change of hepcidin concentration in serum [ Time Frame: 0, 6 and 12 months ]
  • Change of non-transferrin bound iron (NTBI) concentration in serum [ Time Frame: 0, 6 and 12 months ]
  • Change of multiple trace metals in serum [ Time Frame: 0, 6 and 12 months ]
  • Change of intracellular signal molecules, mTOR, NFkB and stress sensor p53 in blood cells [ Time Frame: 0, 6 and 12 months ]
  • Change of 8-oxodG in urine [ Time Frame: 0, 6 and 12 months ]
    Marker of oxidative DNA damage
  • Change of Cu,Zn-SOD activity in erythrocyte hemolysate [ Time Frame: 0, 6 and 12 months ]
    Cu,Zn-Super Oxid Dismutase (SOD)is an antioxidant enzyme
  • Clinical chemistry: Na, K, Ca, Creatinine, creatinine kinase, CRP, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GT), lactate dehydrogenase (LD), albumin, bilirubin. [ Time Frame: 0, 2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks posttreatment ]
    Serum analysis
  • Urine routine test strip for detection of blood, protein, and nitrite [ Time Frame: 0,2,4,6,8 weeks and 3,4,5,6,7,8,9,10,11,12 months ]
    Morning spot urine sample.
  • Ferritin concentration in serum [ Time Frame: 0,2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks post treatment ]
  • Transferrin saturation in serum [ Time Frame: 0,2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks post treatment ]
  • HbA1c [ Time Frame: 0, 2,6,12 months ]
  • INR ( International normalized ratio) [ Time Frame: 0,2,6,12 months ]
  • Analysis of hemoglobin, reticulocytes, hematocrit, MCV, leukocyte count (total and differential), and platelets [ Time Frame: 0, 2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks posttreatment ]
  • Urine trace metals [ Time Frame: 0, 6 and 12 months ]
  • Bone marrow sample [ Time Frame: 0, 6 and 12 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: July 1, 2013)
Pregnancy urin test (hCG) [ Time Frame: 0, 6 and 12 months, 5 weeks posttreatment ]
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Official Title  ICMJE Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.
Brief Summary

Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC.

Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment.

Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine.

Detailed Description

The two most important causes of iron overload disease in humans are the iron-loading disorder hereditary hemochromatosis (HC), and transfusional siderosis in patients with chronic hematological diseases like myelodysplastic syndrome (MDS), thalassemia, and leukemia.

Hemochromatosis. In HC the molecular regulation of iron uptake across the intestinal mucosa is disturbed, leading to hyperabsorption and accumulation of iron in parenchymal tissues such as the liver, pancreas, endocrine organs and heart. Hepcidin, a small peptide hormone synthesized in the liver, apparently functions as the master regulator of systemic iron homeostasis by its ability to control the efflux of iron from the enterocytes and macrophages into blood plasma. This happens by diminishing the iron transfer capacity through the basolateral, transmembrane protein, ferroportin. Expression of hepcidin is carefully adjusted by the iron status of the hepatocytes through a multimolecular signal transducing pathway which acts as a positive feedback mechanism with increased hepcidin synthesis in iron overload (and inflammation). Mutation of one of the signal molecules, leads to inadequate hepcidin synthesis. The most common are the classic C282Y and H63D point mutations of the hemochromatosis protein HFE, which disturbs its interaction with the transferrin receptor 1, the first step in the hepcidin signal cascade. Homozygosity for C282Y is the strongest risk factor for serious iron overload and disease which develops after a long-lasting, asymptomatic period. In Norway the prevalence of C283Y homozygosity is approximately 0.75 in both genders. The preclinical, biochemical phenotype of HC is disclosed by blood tests with elevated transferrin saturation as a marker of hyperabsorption of iron, and increasing ferritin concentration as a surrogate marker of a growing iron overload. As an alternative to liver biopsy, magnetic resonance imaging (MRI) seems to be a powerful non-invasive method to directly assess the iron content of the liver and heart.

Myelodysplastic syndrome and transfusional siderosis. Transfusional iron overload is the result of multiple blood transfusions supplied over a long time period, each of which adds approximately 220 to 250 mg of extra iron to the body. Because iron loading occurs via a parenteral route with the macrophages as the primary target cells, the normal homeostatic mechanisms are not responding adequately and the plasma hepcidin level can be normal or even increased. Even if excess iron is better tolerated in macrophages than in parenchymal cells, a life-threatening iron overload develops much faster with transfusional siderosis than HFE-associated HC. Myelodysplastic syndrome (MDS) is a heterogeneous group of stem cell disorders with inefficient hematopoiesis and increased risk of developing acute myeloid leukemia. The MDS International Prognostic Scoring System (IPSS) which is based on numbers of cytopenias, cytogenetic features and number of blasts in the bone marrow, enables separation of four risk groups with the following median survival years: low-risk patients, 5.7 years; intermediate-1, 3.5 years; intermediate-2, 1.2 years; and high-risk 0.4 years. Many patients become transfusion-dependent and get serious transfusional iron overload. Iron chelation is recommended to low-risk and intermediate-1 patients with probable need of lifelong transfusion therapy.

Consequences of iron overload. If not interrupted, continuous iron loading will at some point start to gradually damage vital organs such as liver, heart and endocrine organs, and lead to serious disease and a shortened lifetime. At the molecular level persistently increased amounts of reactive, small molecular weight iron complexes or the sporadic presence of free iron in blood and tissues, are probably the fundamental pathogenetic mechanism in iron overload. These substances are highly toxic due to their strong ability to catalyze the formation of free radicals such as Reactive Oxygen Species (ROS). The activity of free radicals with damage of native molecules (e.g. DNA) and cellular structures is considered to be the first step in organ and tissue injury. In blood, reactive iron exists as Non-Transferrin Bound Iron (NTBI), mainly in the form of small molecular weight iron-citrate complexes. NTBI is rapidly taken up by the liver and other organs where it adds to the intracellular, reactive labile iron pool (LIP). The presence of NTBI and LIP has been found to correlate with hepatic and cardiac damage in transfusional siderosis and HC. In addition, the homeostasis of other trace metals may be abnormal in iron overload. Little is known about this issue, which warrants a deeper study.

Treatment. In HC, the preferred iron removal therapy is venesection, whilst transfusional iron overload is treated with iron chelators.

Clinical aims of study. The major objective is to determine the efficacy of deferasirox to remove iron from the liver, heart and bone marrow in HC- and MDS-patients with iron overload.

Explorative aims. Determine the correlation between the novel biomarkers hepcidin and NTBI, and ferritin and transferrin saturation in serum; and liver iron concentration (LIC), heart iron concentration (HIC), and bone marrow iron.

Assess the effect of iron overload and iron depletion with either deferasirox or venesection, on the concentration of trace metals in serum and urine in HC and MDS patients.

Study the influence of iron overload and iron depletion with either deferasirox or venesection, on intracellular signal transduction in blood cells isolated from HC and MDS patients.

Study the influence of iron overload and iron depletion with either deferasirox or venesection on oxidative damage of DNA (examined in urine), and the antioxidant status in red blood cells isolated from HC and MDS patients.

Establish reference values for the investigational serum and urine tests in healthy control subjects.

Rationale of the study. The major rationale of the study is related to the need to assess the potential use of deferasirox to treat HC- and MDS-patients with iron overload. However, several "learning objectives" are included: the impact of iron overload and iron depleting treatment on NTBI, hepcidin, markers of oxidative stress, trace metals and intracellular signal transduction molecules.

Although venesection is a safe and effective means of depleting iron in HC patients, it may suppress hepcidin and thus increase iron absorption, particularly at the end of a long treatment period. Also, some HC patients not only feel the cumbersome impact of frequent phlebotomies in daily life, but also experience troublesome side effects.

The subjective perception of venesection side effects was recently communicated in a survey study among 210 HC patients across the United States and some european countries. Of these, 52% of patients undergoing weekly venesections and 37% of the patients in the maintenance phase reported side effects "always" or "most of the time", and 16% would "definitely" or "probably" refuse phlebotomy if they were offered an alternative treatment. Therefore, investigation of the effect of chelator as a potential alternative therapy in HC is warranted. Chelation therapy may not only remove excess iron from the body, but may also counteract formation of reactive, free radicals.

In MDS patients transfusion dependency worsens the survival due to development of damaging iron overload. With every 500 ng/mL increase of s ferritin above the threshold, the risk of death increases by 30%.

Traditionally, iron depletion therapy has been monitored by s-ferritin, which decreases as iron is progressively eliminated. However, s-ferritin is a non-specific parameter which is sensitive to acute phase reactions associated with inflammations, chronic diseases and tissue injury. Furthermore, s-ferritin does not offer information about the burden of free radical production stimulated by reactive iron. For this reason, one aim of this study will be to investigate whether new blood markers like NTBI and hepcidin, along with MRI assessment of LIC and HIC, will improve the diagnosis of iron overload and more accurately identify those patients who are at increased risk of iron induced damage and therefore will benefit from iron depletion therapy.

Iron overload can weaken the cellular antioxidant defence and result in oxidative DNA-damage as the first step in carcinogenesis. Examination of the influence of iron overload and iron depletion with either deferasirox or venesection on oxidative damage of DNA, and on the antioxidant status in red blood cells will be performed.

Increased knowledge of how intracellular signal transduction is influenced by cellular iron and use of deferasirox may provide new insights into the molecular pathogenesis of iron overload. This will be examined in single leukocyte cell flowcytometry assays of the following intracelluar signal parameters: stress sensor p53, mTOR and NFkB.

Finally, little is known about how iron overload interacts with the metabolism of other trace metals. The concentration of a broad spectrum of trace metals in serum (S) and urine (U) will be monitored throughout the study period by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) (28) : boron (S,U), barium (S,U), beryllium (S,U), cadmium (S,U), cobalt (S,U), cesium (S,U), copper (S,U), mercury (U), lithium (U), manganese (S), molybdenum (S), nickel (S,U), lead (S,U), antimony (S,U), selenium (S,U), tin (S,U), strontium (S,U), thallium (S,U), tungsten (S), yttrium (S,U), zinc (S,U).

The tolerability of deferasirox will also be assessed throughout the study, either as sole treatment in MDS patients or compared to venesection in HC patients.

Healthy volunteers are used solely as controls to determine the normal blood concentration of the biomarkers and tests which will be performed in the patients. The controls will not be treated.

Previous clinical trials in HC and MDS. Deferasirox has been studied in a variety of diseases with transfusional iron overload, particularly in thalassemia. It has a favorable profile with respect to efficacy, safety and tolerability. However, controlled clinical studies with deferasirox in HC and MDS are limited.

The study by Phatak et al (2010) was the first clinical trial to demonstrate the safety and efficacy of deferasirox in patients with C282Y-homzygot hemochromatosis. They showed that serum ferritin levels were reduced similarly in two cohorts given respectively 10 mg/kg/day and 15 mg/kg/day of deferasirox. Since the dose of 15 mg/kg/day caused a higher frequency of adverse events (AEs), they recommended a staring dose of 10 mg/kg/day to be most appropriate in HC- patients. The most important AEs were associated with an increase in serum creatinine and liver enzymes. The study was limited by pretreatment of some patients with phlebotomy prior to the deferasirox study; in addition, many of the patients had only mild iron overload. For this reason, we see no argument to use a higher dose in our study, and therefore we choose a starting deferasirox dose of 10 mg/kg/day in HC- patients.

In a recent study, 24 heavily transfused MDS patients were enrolled to receive 52 weeks of deferasirox therapy. Deferasirox was well tolerated and effectively reduced LIC, labile plasma iron and s-ferritin in patients completing 24 to 52 weeks of therapy, despite ongoing receipt of red blood cell transfusions. In addition to reducing long-term toxicity of iron overload, chelation therapy has shown beneficial effects on hematopoiesis in a small proportion of MDS patients. One ongoing study comparing deferasirox with placebo was found in Cochrane search carried out in June 2010.

Pharmacokinetics of deferasirox. Deferasirox (Exjade®) is a bivalent iron chelator which is taken orally as a tablet, once per day. It is readily absorbed and reaches peak concentration in blood after 1 to 2 hours. The half-life is 12 to 17 hours, and effective levels of active chelator are maintained in the blood for more than 24 hours. The drug is eliminated via the hepatobiliary system. The dose varies from 10 mg/kg/day in patients with mild iron overload to 30 mg/kg/day in patients with overt iron toxicity.

Adverse events (AEs) of deferasirox. The most frequent adverse clinical events are gastrointestinal disturbances and skin rash. The most frequent laboratory side effects are mild increase in serum creatinine and liver transaminases. The adverse events have for the most part been reported in patients with transfusional iron overload. In HC patients the data are more scarce due to the very few studies that have been performed in this group. Other common AEs include headache, constipation, abdominal distension, dyspepsia, pruritus, and proteinuria. Less common AEs include anxiety, sleep disorder, dizziness, early cataract, maculopathy, hearing loss, pharyngolaryngeal pain, gastrointestinal hemorrhage, gastric ulcer, duodenal ulcer, gastritis, oesophagitis, hepatitis, cholelithiasis, pigmentation disorder, renal tubulopathy, glycosuria, pyrexia, edema, and fatigue.

Adverse reactions reported during post-marketing experience include pancytopenia, hypersensitivity reaction, hepatic failure, leukocytoclastic vasculitis, urticaria, erythema multiforme, alopecia, acute renal failure, and tubulointerstitial nephritis, gallstones and related biliary disorders, elevations of liver transaminases, and hepatic failure. Any such adverse events will be recorded in the subject's Case Report Form (CRF).

Study design.

The study incorporates 4 arms, which will recruit in parallel:

Arm 1: (open, randomized, comparative) will consist of 10 patients with confirmed HC, who will be randomized to receive standard treatment with venesection (withdrawal of 450 mL blood every 8 to 10 days).

Arm 2: (open, randomized, comparative) will consist of 10 patients with confirmed HC, who will be randomized to receive investigational treatment with deferasirox (10 mg/kg orally given once daily) for a period of 12 months;

Arm 3: (open, non-comparative) will consist of 20 patients with confirmed MDS, all of whom will receive investigational treatment with deferasirox (initially 10 mg/kg orally given once daily, can be increased to max 40 mg/kg) for a period of 12 months;

Arm 4: will consist of 10 healthy volunteers who will undergo the same screening assessments (i.e. with respect to relevant exclusion criteria) and will act as non-treated normal controls for comparison of investigational blood tests.

The study will be non-blinded. Subjects and investigators will be aware of their subject and treatment arm.

Subjects will undergo assessments at screening (within 1-14 days prior to baseline), and for patients at baseline Day 0, and at 2,4,6,8 weeks, and thereafter monthly until 12 months, and at follow up 4-6 weeks after treatment has been completed. Healthy controls will be examined at screening, 2,6 and 12 months. Study-specific assessments will include physical examinations/vital signs, sampling of blood, urine, and for patients only: bone marrow and MRI to assess the effect of iron overload and iron reduction treatment on the following:

  • Conventional tests to indicate iron overload: ferritin and transferrin saturation in serum; LIC and HIC, bone marrow iron content using microscopy.
  • Hepcidin concentration in serum;
  • NTBI concentration in serum;
  • Intracellular signal transduction parameters: Analysis of the stress sensor p53, NFkB, and mTOR in leukocytes from peripheral blood;
  • Trace metal concentrations in serum and urine;
  • Antioxidant capability in blood hemolysate: Cu,Zn-SOD;
  • Free radical damage to DNA and RNA: 8-oxodG concentration in urine;
  • For MDS patients: number of transfusions;
  • For HC and MDS patients: number of hospitalizations and overall survival;
  • Safety and tolerability.

For patients and controls, samples of peripheral blood will be taken pre-dose, and at 24 hours after dosing, for assessment of stress sensor p53, NFkB, and mTOR.

Interim assessments. Routine blood and urine tests will be performed for patients at 2,4,6,8 weeks, and thereafter monthly until 12 months and at follow up 4-6 weeks after end of treatment for monitoring the disease, for safety reasons, and to obtain data for comparison traditional biomarkers with the new investigational biomarkers hepcidin and NTBI.

Volunteers will undergo all safety assessments plus investigational blood and urine tests. They will not undergo MRI, bone marrow examinations, registrations of transfusions, or active treatment with deferasirox or venesection.

Patients with HC or MDS will undergo a follow-up assessment 4 to 6 weeks after last dose. At this visit, all safety assessments and investigational blood and urine tests, including a pregnancy test, will be repeated, but MRI and bone marrow examination will not be performed. Volunteer controls will not attend for this visit.

This is an exploratory study with no sample size calculation and no minimum enrollment requirement. It is anticipated that a maximum of 40 patients will be enrolled in order to obtain at least 30 patients fulfilling the study criteria; 10 volunteers will also be enrolled.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Hemochromatosis
  • Myelodysplastic Syndromes
Intervention  ICMJE
  • Drug: Deferasirox
    Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
    Other Name: Exjade
  • Other: Venesection
    Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
  • Drug: Deferasirox
    Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
    Other Name: Exjade
Study Arms  ICMJE
  • Active Comparator: Deferasirox HC
    10 patients with hemochromatosis treated with Deferasirox
    Intervention: Drug: Deferasirox
  • Active Comparator: Venesection HC
    10 patients with hemochromatosis treated with venesection
    Intervention: Other: Venesection
  • Active Comparator: Deferasirox MDS
    20 patients with myelodysplastic syndrome treated with Deferasirox
    Intervention: Drug: Deferasirox
  • No Intervention: Controls
    10 healthy control persons to assess the normal level of investigational blood tests.
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: July 1, 2013)
50
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 2017
Actual Primary Completion Date January 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with hemochromatosis, aged > 30 years, C282Y- homozygote, with serum-ferritin =/> 1000 µg/L
  • Patients aged > 18 years with verified low-risk or intermediate-1 risk of myelodysplastic syndrome, with normal cytogenetics and serum-ferritin > 1500 µg/L, or with a transfusion history of =/> red- blood-cell-transfusions.

Exclusion Criteria:

  • Previous or current venesection
  • MDS patients eligible for hematopoietic stem cell transplantation
  • Subject complies with one or more of the following standard exclusion criteria for MRI examination;

    • If the patient has a pacemaker.
    • If the patient has a neurostimulator
    • If the patient has a "aneurismeclips"
    • If the patient has a foreign object in the eye. If yes, what object.
    • If the patient has a cochlea-/earimplant.
    • If the patient has a V/P shunt.
    • If the patient is claustrophobic.
    • If the patient has an artificial heart valve.
    • If the patient has known renal failure, eGFR <30.
    • If the patient has or will have a liver transplantation.
    • Other: metal prostheses, metal implant
  • Presence of inflammation (CRP ≥ 5 mg/L)
  • Presence of proteinuria or creatinine > 2 x UNL (Upper Normal Limit)
  • Estimated glomerular filtration rate (GFR) < 60 mL/min
  • ALAT, ASAT, GT or ALP > 2 x ULN ( Upper Normal Limit)
  • ALAT > 90 U/L for women, ALAT > 140 U/L for men
  • ASAT > 70 U/L for women, ASAT > 90 U/L for men
  • ALP > 210 U/L for women and men
  • GT > 90 U/L for women ≤ 40 years, GT > 150 U/L for women > 40 years
  • GT > 160 U/L for men ≤ 40 years, GT > 230 U/L for men > 40 years
  • Acute or chronic hepatitis
  • Patients with chronic liver disease Child Pugh Class B and C
  • Chronic skin disease with rash
  • Estimated survival < 6 months
  • Prior or concomitant treatment with other iron chelator therapies within 6 weeks of screening
  • History of non-compliance to medical regimens, or considered potentially unreliable and/or not cooperative
  • Uncontrolled diabetes, defined as glycolated hemoglobin (HbAlc) > 8.5%
  • Presence of cataracts or hearing loss disease
  • Presence of a surgical or medical condition which might significantly alter absorption, distribution, metabolism or excretion of study drug
  • Planned in-hospital surgeries during the course of the study
  • Subjects who are pregnant, breast-feeding, or intending to become pregnant
  • Hypersensitivity to the active substance or the excipients in drug product
  • Any other reason why, in the opinion of the investigator, the patient should not participate (e.g. serious heart disease, infection, cancer, etc).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Norway
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01892644
Other Study ID Numbers  ICMJE 2012/2139
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Haukeland University Hospital
Study Sponsor  ICMJE Haukeland University Hospital
Collaborators  ICMJE Novartis
Investigators  ICMJE
Principal Investigator: Rune J Ulvik, MD, PhD Dept. of Clinical Science and Lab. of Clinical Biochemistry, Univ. of Bergen and Haukeland University Hospital, Bergen, N5021, Norway
PRS Account Haukeland University Hospital
Verification Date January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP